Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q2 2025 value amounting to -$0.99.

  • KalVista Pharmaceuticals' EPS (Basic) rose 747.66% to -$0.99 in Q2 2025 from the same period last year, while for Apr 2025 it was -$3.77, marking a year-over-year decrease of 3464.29%. This contributed to the annual value of -$3.69 for FY2025, which is 718.43% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.99 for Q2 2025, which was up 747.66% from -$0.87 recorded in Q3 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' EPS (Basic) peaked at -$0.84 during Q1 2024, and registered a low of -$1.07 during Q2 2024.